Shares of Venus Remedies Limited witnessed a strong bullish wave in today’s trading session, surging over 4% to hit an intraday high of ₹1,077.80. The sudden price movement followed a major regulatory milestone, with the company securing its first global marketing authorization for its specialty oncology therapy, Plerixafor, from the Saudi Food and Drug Authority (SFDA). The corporate disclosure, filed under SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, triggered immediate buying interest. The stock opened at ₹1,030.00 and quickly rallied to gain ₹41.80 (4.06%) by mid-day, trading close to its 52-week high of ₹1,088.80 with a robust volume of 44,628 shares.
This regulatory milestone marks the first time the Panchkula-based pharma major has secured marketing authorization for Plerixafor anywhere in the world. Plerixafor is a complex, hematopoietic stem cell mobilizer used in combination with G-CSF for autologous transplantation in patients suffering from acute hematological malignancies, specifically multiple myeloma and non-Hodgkin lymphoma. Company management highlighted that this breakthrough is a deliberate step away from a reliance on volume-driven commodity injectables, moving the firm decisively into higher-value, high-margin specialty segments across regulated global healthcare markets.
The timing of the approval positions Venus Remedies perfectly to capture a rapidly expanding Middle Eastern healthcare market. The Saudi Arabian pharmaceutical sector is projected to expand from USD 12.1 billion in 2026 to USD 17.1 billion by 2033, compounding at a CAGR of 5.0% under the region’s Vision 2030 economic transformation plans. Furthermore, the broader GCC stem cell therapy market was valued at USD 1.2 billion in 2024, with Saudi Arabia commanding the lion’s share of demand. The company intends to commercialize Plerixafor (24mg/1.2ml) through its existing international business network, prioritizing direct partnerships with tertiary oncology centers across the kingdom.
Street analysts note that the market’s enthusiastic reaction is heavily anchored in Venus Remedies’ highly attractive fundamental structure. At the current market price, the company commands a market capitalization of ₹1,379 Crore. It trades at a trailing price-to-earnings (P/E) ratio of just 18.07, representing a significant discount to the broader Industry P/E of 34.60. Backed by a trailing EPS of 57.09, a Price-to-Book (P/B) ratio of 2.32, and a virtually debt-free balance sheet with a Debt-to-Equity ratio of 0.02, the company boasts the financial flexibility required to fund its aggressive international distribution strategy.
Disclaimer: This article is generated for informational purposes only and does not constitute financial, investment, or trading advice. The data and analysis presented are based on publicly available market information at the time of writing. Markets are subject to risk. Please consult a qualified financial advisor before making any investment or trading decisions. Business Upturn does not accept responsibility for any losses arising from reliance on this content.